Cancer Therapy

Remedyne announces a license agreement for development of a cancer immunotherapeutic

Published in Gene Therapy Weekly, April 4th, 2002

Remedyne Corp. has announced that they have signed a licensing agreement with Bayer Corp. (BAY) involving a promising tumor antigen for use in Remedyne's lead cancer immunotherapeutic.

The antigen is carcinoembryonic antigen (CEA), which is commonly expressed by a wide range of cancers, including 50-90% of colorectal, gastric, and pancreatic cancers, lung and breast cancers. These CEA expressing cancers represent the majority of cancer deaths worldwide.

Under the agreement Remedyne obtains a license to use the gene to develop RemeStim-CEA for the U.S. oncology market. It is hoped that research will lead to the development of a product designed to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry